Table 1. Clinical characteristics and results for melanoma patients and healthy volunteers.
Donora) | Stage | Tumor Burden | HLA-A 1 | HLA-A 2 | HLA-B 1 | HLA-B 2 | HLA-C 1 | HLA-C 2 | Identified Peptides | 8-11mers | 8-11mers (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
P1 | stage IV | low | A*02 | A*26 | B*27 | B*44 | C*02 | C*05 | 389 | 272 | 69.9 |
P2 | stage IV | medium | A*02 | A*03 | B*44 | B*47 | C*05 | C*06 | 633 | 502 | 79.3 |
P3 | stage IV | high | A*02 | A*02 | B*35 | B*40 | C*03 | C*04 | 972 | 813 | 83.6 |
P4 | stage IV | high | A*02 | A*32 | B*51 | B*57 | C*06 | C*14 | 558 | 385 | 69.0 |
P5 | stage IV | high | A*02 | A*03 | B*15 | B*40 | C*02 | C*07 | 730 | 608 | 83.3 |
P6 | stage III | none | A*02 | A*03 | B*51 | B*55 | C*03 | C*16 | 437 | 309 | 70.7 |
P7 | stage III | none | A*02 | A*02 | B*52 | B*58 | C*03 | C*12 | 418 | 321 | 76.8 |
P8 | stage IV CR | low | A*02 | A*26 | B*27 | B*44 | C*02 | C*05 | 306 | 212 | 69.3 |
H1 | healthy | A*02 | A*03 | B*18 | B*57 | C*06 | C*07 | 568 | 457 | 80.5 | |
H2 | healthy | A*02 | A*03 | B*39 | B*44 | C*07 | C*07 | 563 | 423 | 75.1 | |
H3 | healthy | A*02 | A*03 | B*07 | B*15 | ntb) | nt b) | 664 | 536 | 80.7 | |
H4 | healthy | A*02 | A*02 | B*44 | B*40 | nt b) | nt b) | 377 | 271 | 71.9 |
P1 to P8 denote melanoma patients, H1 to H4 denote healthy volunteers
Not tested